Cargando…
Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection
There is limited information available concerning the effect of thymalfasin (Tα1) as an adjuvant therapy in hepatocellular carcinoma (HCC) patient who received liver resection. The present study aimed to evaluate whether Tα1 can improve the prognosis of small HCC patients after liver resection. A to...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406071/ https://www.ncbi.nlm.nih.gov/pubmed/28422855 http://dx.doi.org/10.1097/MD.0000000000006606 |